Treatment of Peri-Portal Leiomyosarcoma
Complete surgical resection with R0 margins is the primary treatment for peri-portal leiomyosarcoma, requiring en bloc resection of involved structures including portal vein reconstruction and hepatectomy as needed 1, 2.
Surgical Approach
The cornerstone of treatment is aggressive surgical resection performed at a specialized sarcoma and hepatobiliary center. Based on recent case evidence, the surgical strategy should include:
- En bloc resection of the tumor with all involved structures (portal vein, hepatic parenchyma, bile duct if necessary)
- Portal vein reconstruction using autogenous vein grafts (external iliac vein interposition) when the portal vein is involved 2
- Right hepatectomy if the tumor involves the right portal branch or hepatic parenchyma 1, 2
- Biliary reconstruction via Roux-en-Y hepatico-jejunostomy when biliary confluence is involved 2
The goal is achieving R0 resection, which is the most critical factor for prolonged survival in these rare tumors 2.
Systemic Therapy Considerations
For Localized Disease
Adjuvant chemotherapy is not standard treatment but can be offered as an option for high-risk patients (high-grade, deep, >5 cm tumors) through shared decision-making 3. The evidence for adjuvant therapy in soft tissue sarcomas remains conflicting, with the largest studies showing negative results.
For Metastatic or Unresectable Disease
If the tumor is unresectable at presentation, neoadjuvant chemotherapy should be administered to achieve tumor shrinkage and enable subsequent R0 resection 4. The recommended regimen for leiomyosarcoma specifically is:
First-line: Doxorubicin plus dacarbazine 5. This combination is preferred over anthracycline plus ifosfamide for leiomyosarcoma, as retrospective evidence suggests ifosfamide is less active in this histologic subtype 5, 6.
Alternative first-line options:
- Gemcitabine plus docetaxel (particularly active in leiomyosarcoma) 7, 3
- Single-agent doxorubicin if multiagent therapy is not tolerated 5
For Recurrent or Progressive Disease
Second-line options after anthracycline failure 5, 3:
- Trabectedin - proven effective specifically in leiomyosarcoma [II, B evidence] 5, 3
- Gemcitabine plus dacarbazine - improves overall survival and progression-free survival in leiomyosarcoma [II, B evidence] 5, 3
- Pazopanib - provides 3-month progression-free survival benefit in non-adipogenic sarcomas [I, B evidence] 5, 3
- Gemcitabine monotherapy - has demonstrated activity in leiomyosarcoma 5, 3
Critical Pitfalls to Avoid
- Do not attempt resection at non-specialized centers - these complex procedures require expertise in both sarcoma surgery and hepatobiliary/vascular reconstruction 1
- Do not use ifosfamide-based regimens as first-line for leiomyosarcoma - evidence suggests inferior activity compared to dacarbazine-based regimens 5, 6
- Do not delay surgery if R0 resection is achievable - complete surgical excision offers the only chance for cure 2
- Ensure core needle biopsy confirmation before proceeding with treatment planning 2, 8
Surveillance Strategy
Following R0 resection, close surveillance is essential as distant recurrence occurs in 27.8% of patients with localized disease 9. Deep tumor location and high-grade histology are the strongest predictors of distant recurrence 9. Local recurrence is rare (7.1%) in peripheral vein leiomyosarcomas 9, though data specific to portal vein origin is limited.
Radiotherapy has minimal role in portal vein leiomyosarcoma given the low local recurrence rates and anatomical constraints 9. It should only be considered for unresectable disease or positive margins where re-resection is not feasible 7.